Open-Label Study to Evaluate Safety of A Single Dose of SYM-1219

Summary

This is a Phase 3, multi-center, prospective, open-label study to evaluate the safety of SYM-1219 granules containing 2 grams of secnidazole in women and postmenarchal adolescent girls with bacterial vaginosis.

Timeline

Start

2015-06

Primary completion

2015-10

Completion

2015-10

Drugs

Indications